Skin response to pressure and ageing.

P. Thirumalaikolundusubramanian,A. Askari

Saudi Medical Journal

Abstract:Full text is available as a scanned copy of the original print version.

What problem does this paper attempt to address?

Metastatic Ovarian Tumor from Pancreatic Cancer Treated with Combined Immunotherapy: A Case Report

Yiying Tao,Lei Tang,Li Zuo,Yue Ma,Fengchun Zhang,Yingchun Xu

DOI: https://doi.org/10.3892/ol.2022.13464

2022-01-01

Oncology Letters

Abstract:Pancreatic cancer (PC) is a fatal disease with a high mortality rate due to difficulties in early diagnosis and metastasis. Common sites of metastasis from PC include the liver, lung, stomach and kidney. Patients diagnosed at already the metastatic stages on presentation constitute 50-55% of the cases, with a 5-year survival rate of 3%. By contrast, secondary ovarian metastases account for 10-25% of all ovarian malignancies, though an accurate diagnosis remain challenging. The present study reports the rare case of a 42-year-old woman with primary hepatic metastasis and secondary ovarian metastasis from PC treated with two lines of immunotherapy, who is also experiencing severe treatment-associated toxicity. The patient first received combined immunotherapy consisting of camrelizumab (200 mg; day 1; every 3 weeks) and chemotherapy with nab-paclitaxel (125 mg/m(2); days 1 and 8; every 3 weeks) and gemcitabine (1,000 mg/m(2); days 1 and 8; every 3 weeks). She then exhibited a partial response following 4 months of treatment. However, 9 months after the initial treatment, the disease progressed with ovarian involvement, which was confirmed by surgery. Second-line treatment included immunotherapy, targeted therapy and oral chemotherapy (200 mg sintilimab on day 1; 50 mg tegafur from days 1-14, twice daily; and 8 mg anlotinib from days 1-14, every 3 weeks). The progression-free survival time from this second-line treatment was 6 months. Immunotherapy was permanently aborted due to severe intestinal inflammation, where four lines of combined treatments were recommended. The patient remains on treatment with a good quality of life in July 2022, and a current overall survival time of >24 months. In conclusion, the diagnosis of metastatic PC leads to a poor prognosis, but ovarian metastasis from PC is rare. Furthermore, the combination of immunotherapy with chemotherapy or antiangiogenic inhibitors shows promise as a treatment strategy for advanced stages of PC.
[A Case of Breast Metaplastic Carcinoma and Distant Metastasis with Complete Response to Immunotherapy]

Yoshihiro Kitayama,Takemi Sugimoto,Hideaki Ishikawa,Yousuke Yoden

Abstract:An 82-year-old woman visited our hospital complaining of a rapidly growing hemorrhagic mass with ulceration of the right breast. A CT scan revealed a circumscribed, lobulated mass of approximately 14 cm diameter, with coarse calcifications, which had invaded the skin and major pectoral muscle and with metastasis in the both lungs. She underwent a total mastectomy with major pectoral mastectomy. The pathological findings were spindle cell carcinoma admixed with chondroid metaplasia and an osteoid-like appearance; therefore, metaplastic breast cancer was diagnosed. Biweekly drip infusion of immune checkpoints inhibitor were administered as immunotherapy, which yielded a complete response of lung matastasis. Administration of monthly immune checkpoints inhibitor resulted in no recurrence for 3 years after the operation. Accumulation of further similar cases and development of a novel effective treatment are desired.
Programmed Cell Death-1 Inhibitor Combination Treatment for Recurrent Proficient Mismatch Repair/ Miscrosatellite-Stable Type Endometrial Cancer: A Case Report.

Chong-Ya Zhai,Lu-Xi Yin,Wei-Dong Han

DOI: https://doi.org/10.12998/wjcc.v10.i21.7474

2022-01-01

World Journal of Clinical Cases

Abstract:BACKGROUND:Endometrial cancer (EC) is one of the most common cancers of the female reproductive tract, and the incidence is increasing rapidly. Immunotherapy using programmed cell death-1 (PD-1) inhibitors is an emerging research topic and treatment strategy for refractory gynecological malignancies. However, clinical management of EC with checkpoint inhibitors requires improvement. Herein, we discuss a case of refractory proficient mismatch repair (pMMR)/miscrosatellite-stable (MSS) EC treated with a combination of PD-1 and angiogenesis inhibitors and offer a review of the pathophysiology and clinical outcomes based on previous studies.CASE SUMMARY:A 62-year-old woman diagnosed with invasive or metastatic EC in 2015 was treated with six courses of chemotherapy and refused further radiotherapy. Four years later, she developed chest pain, and lung biopsy indicated thyroid transcription factor-1 (-), Napsin A (-), estrogen receptor (+), progesterone receptor (+), anaplastic lymphoma kinase (D5F3) (-), and receptor tyrosine kinase (D4D6) (-) metastatic EC. Genetic testing results showed low tumor mutation burden, pMMR, PD ligand 1 (-), MSS, and HLA-class 1 heterogeneous disease. The patient was started on toripalimab combined with nab-paclitaxel for seven cycles (every 3 wk), but this regimen was terminated because of an intolerable chemotherapy adverse event. The disease progressed in 2020, and the patient's treatment was switched from nab-paclitaxel to anlotinib, while immunotherapy using toripalimab was continued. The patient achieved a major partial response with well-tolerated toxicities, and treatment is ongoing.CONCLUSION:Molecular testing is advised for clinical classifications of EC owing to its high heterogeneity. In this case, the patient had pMMR/MSS EC and achieved a positive outcome with combination PD-1 inhibitor treatment. These results warrant further clinical exploration.
Harnessing Listeria monocytogenes to target tumors

C. Gravekamp,Y. Paterson

DOI: https://doi.org/10.4161/cbt.9.4.11216

2010-02-15

Cancer Biology & Therapy

Abstract:Because of its cytosolic localization, Listeria monocytogenes (LM) has long been considered an attractive tool for delivering tumor-associated antigens (TAA) antigens in vivoto combat cancer. LM directly infects antigen-presenting cells (APC) such as monocytes, macrophages and dendritic cells (DC), thereby delivering the TAA into their cytoplasm, resulting in processing, and presentation of the antigen to the immune system. This activates adaptive and innate immune responses to the TAA, mediating tumor cell cytolysis. Recently we discovered additional pathways by which Listeria can be harnessedto induce tumor cell death, which suggest new directions in the development of vaccines or therapies against cancer. In one approach, we have used Listeria to induce immune responses that destroy tumor vasculature. Another new pathway involves selective infection of cancer cells with Listeria, followed by tumor cell death through the production of high levels of reactive oxygen species (ROS) and through Listeria-specific cytotoxic T lymphocytes (CTL). This review will focus on the most recent studies on the multiple pathways of LM and how they can be harnessed in the battle against cancer.
Case Report: Long-Term Response to Pembrolizumab Combined With Endocrine Therapy in Metastatic Breast Cancer Patients With Hormone Receptor Expression

Dingyong Wu,Shu Tang,Rong Ye,Dongmei Li,Dejian Gu,Rongrong Chen,Huan Zhang,Jianguo Sun,Zhengtang Chen

DOI: https://doi.org/10.3389/fimmu.2021.610149

IF: 7.3

2021-02-22

Frontiers in Immunology

Abstract:Breast cancer is one of the most commonly diagnosed malignancies. Although endocrine therapy improves the survival of patients with hormone receptor (HR)-positive breast cancer, the post-endocrine therapy strategy for metastatic breast cancer remains challenging. Herein, we report two patients who benefited from antiestrogen agents combined with an immunotherapy regimen to support the notion that an immunotherapy combination regimen may be a potential treatment for patients with HR-positive metastatic breast cancer post-endocrine therapy. Case 1 involved a patient with relapsed breast cancer with ovarian and brain metastases after endocrine therapy. After undergoing surgery for the ovarian lesions, she received three cycles of chemotherapy. Given that the lesions in the brain did not change, chemotherapy was discontinued. A high T cell receptor (TCR) repertoire (high Shannon index and clonality) was observed in the tumor. Considering the patient's preference and safety, and the efficacy of immunotherapy, she was administered with letrozole combined with pembrolizumab. The patient achieved a partial response, and the progression-free survival (PFS) was more than 21 months. Case 2 involved a patient with breast cancer with multiple bone metastases. After failure of combined radiotherapy and chemotherapy, the patient received tamoxifen combined with pembrolizumab based on the patient's preference and clinical biomarkers of a positive differentiation cluster of eight tumor-infiltrating lymphocytes and a high TCR repertoire (high Shannon index and clonality) in the tumor. The patient's bone pain and biomarkers were relieved after the treatment. The patients completed six cycles of pembrolizumab, and the PFS was more than 21 months. In conclusion, our study confirmed that antiestrogen agents combined with an immunotherapy regimen is a promising treatment for patients with HR-positive metastatic breast cancer.

immunology
Long Survival after Immunotherapy Plus Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma: A Case Report and Review of Literature

Meng-Ye He,Fei-Fei Yan,Kai-Li Cen,Peng Shen

DOI: https://doi.org/10.12998/wjcc.v10.i32.11889

2022-01-01

World Journal of Clinical Cases

Abstract:BACKGROUND Intrahepatic cholangiocarcinoma (iCCA) is the second most common primary hepatic malignancy worldwide. However, currently available systemic therapies are of limited effectiveness, and the median overall survival of patients treated with first-line standard chemotherapy is less than one year. Immune checkpoint inhibitors have been used to treat solid tumors. Clinical studies recently explored the combination of chemotherapy and immunotherapy for CCA. However, the clinical significance of predictive biomarkers for chemo-immunotherapy in CCA remains unclear. It is also worth exploring whether a combination of chemotherapeutic agents can increase the sensitivity of CCA immunotherapy. CASE SUMMARY This study reports a case of advanced iCCA in which clinical complete remission had been achieved using a programmed death 1 (PD-1) inhibitor and paclitaxel without known predictive biomarkers, but with BRCA1, KRAS, and NTRK3 mutations after rapid progression to first-line chemotherapy, and has remained in clinical complete remission for more than two years. This case suggests that chemo-immunotherapy is a potential therapeutic option for patients with iCCA and few known predictive biomarkers for immunotherapies as well as synergistic effect of the combination of paclitaxel and PD-1 monoclonal antibody. CONCLUSION The combination of paclitaxel and PD-1 monoclonal antibodyr can be explored in patients with advanced iCCA.
Case Report: Significant Response to Immune Checkpoint Inhibitor Camrelizumab in a Heavily Pretreated Advanced ER+/HER2− Breast Cancer Patient With High Tumor Mutational Burden

Rong Wang,Yuchen Yang,Wei-Wu Ye,Jianxing Xiang,Songan Chen,Wei-Bin Zou,Xiao-Jia Wang,Tianhui Chen,Wen-Ming Cao

DOI: https://doi.org/10.3389/fonc.2020.588080

IF: 4.7

2021-02-09

Frontiers in Oncology

Abstract:Endocrine treatment plus CDK4/6 inhibitors have become standard of care for estrogen receptor positive (ER+) breast cancer. Although immune checkpoint inhibitors (ICIs) have shown promising antitumor activity in a variety of cancer types, only limited success has been achieved for metastatic breast cancer (mBC) patients, especially the ER+ subtype, which usually exhibit lower tumor mutation burden (TMB) compared with other subtypes and therefore perceived as immunologically quiescent. Here we present a case of an ER+/HER2- but TMB-high mBC patient who had significant response to combination therapy with anti-PD-1 antibody camrelizumab and vinorelbine and obtained partial response (PR) with a progression-free survival (PFS) of 5 months after failure of multiple lines of therapy. Our case indicates that TMB may serve as a potential biomarker in immunotherapy selection for normally immunologically “cold” tumors such as ER+ mBC, also molecular monitoring during the whole treatment course plays an important role in patient management.

oncology
A Metastatic Intrahepatic Cholangiocarcinoma Treated with Programmed Cell Death 1 Inhibitor: a Case Report and Literature Review

Jingjing Zhang,Lihua Wu,Jian Liu,Meihua Lin

DOI: https://doi.org/10.2217/imt-2019-0100

2020-01-01

Immunotherapy

Abstract:Intrahepatic cholangiocarcinoma is a disease with grave prognosis due to limited therapeutic regimens. Programmed cell death 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitor have shown dramatic clinical effectiveness in multiple solid tumors. Here, we report the case that a patient with metastasis intrahepatic cholangiocarcinoma, being failure of first-line chemotherapy, was enrolled into the Phase I study of a PD-1 inhibitor, sintilimab. The patient achieved complete remission after three cycles of treatment with mild adverse reaction. In addition, the tumor mutational burden and the microsatellite instability status were low in the present case. Hence, PD-1 inhibitor might be a promising therapeutic approach for patients with advanced cholangiocarcinoma.
Long-Lasting Complete Remission in a Patient With Metastatic Metaplastic Breast Cancer Treated With Immune Checkpoint Inhibitor and Chemotherapy: A Case Report and a Review of the Literature

Aydah Al-Awadhi,Safia Alnaqbi,Alia Albawardi

DOI: https://doi.org/10.7759/cureus.53419

2024-02-01

Cureus

Abstract:Metaplastic breast cancer (MpBC) is a rare form of breast cancer known for suboptimal response to chemotherapy, high recurrence rate, poor prognosis, and limited treatment options. Recent studies have reported that MpBC has high expression of programmed death ligand 1 and tumor-infiltrating lymphocytes, indicating the potential effectiveness of immunotherapy (IO) in MpBC. In addition, several reports have demonstrated the activity of IO in MpBC. In this case report, we present a case of recurrent MpBC that achieved durable, rapid, complete remission with atezolizumab (anti-PD-L1) and nab-paclitaxel with a continued response even after discontinued therapy.
A case report of a dramatic response to olaparib in a patient with metastatic pancreatic cancer harboring a germline BRCA2 mutation.

Huan Wang,Chenyu Mao,Ning Li,Liping Sun,Yulong Zheng,Nong Xu

DOI: https://doi.org/10.1097/MD.0000000000017443

IF: 1.6

2019-01-01

Medicine

Abstract:Rationale: Pancreatic cancer (PC) is considered as one of the deadliest cancers all over the world. Germline and somatic BRCA1/2 mutations have been widely studied in breast and ovarian carcinomas as they have been found to enhance the risk for disease progression. Olaparib, an oral poly(adenosine diphosphate-ribose)polymerase (PARP) inhibitor, has been approved for the treatment strategy of ovarian cancer with any BRCA1/2 mutations. There is a lack of studies which focus on the treatment of other cancer with BRCA-Mutation. Patient concerns: This report describes a patient whose presenting complaints were "Physical examination showed that the pancreas was occupied for one month." He initially was diagnosed with stage IV PC based on conventional imaging and pathologic assessment. He had a known germline BRCA 2 mutation, which exhibited a good response to PARP inhibitor therapy. Diagnosis: Through the biopsy histopathological examination, imaging examination, and genetic testing, the patient was diagnosed as metastatic PC with BRCA2 mutation. Interventions: He received gemcitabine and albumin-bound paclitaxel chemotherapy from March 15, 2017 to June 30, 2017, and Nivolumab immunotherapy as the maintenance therapy. After serum CA-199 level increased, Olaparib was orally administered from August 17, 2017 to March. After tumor relapsed, he received multiple lines of chemotherapy, including Trametinib Oxaliplatin, S-1, bevacizumab, and irinotecan liposome injection till July 17, 2018. Outcomes: We observed the patient had a good progression-free survival (7.4 months); the lesion of the pancreas was classified as partial disease through Olaparib treatment, which indicated significant shrinkage. But it is difficult to conclude whether such therapy could help prolong the overall survival for such patients. Lessons: The targeted therapy Olaparib showed early signs of potential in treating PC in patients with mutations of the BRCA genes. With emerging therapeutic modalities and next-generation sequencing development, it is increasingly relevant to consider mutation screenings of patients with PC.
Metastatic pancreatic and lung cancer patient in complete remission following immunotherapy: A case report and review of literature

Joaquina Martínez-Galán,Cristina Jiménez-Luna,Isabel Rodriguez,Elisabeth Maza,Carlos García-Collado,Antonio Rodríguez-Fernández,Javier Luis López-Hidalgo,Octavio Caba

DOI: https://doi.org/10.4251/wjgo.v16.i5.2233

2024-05-08

World Journal of Gastrointestinal Oncology

Abstract:BACKGROUND Metastatic pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with dispiriting survival data. Immunotherapy is a promising approach to many cancer types, but achieves poor outcomes in advanced PDAC due to its immunosuppressive tumor microenvironment. We describe a case of metastatic PDAC effectively treated with pembrolizumab. CASE SUMMARY We report the case of a 67-year-old woman with unresectable locally advanced PDAC, treated with gemcitabine plus nab-paclitaxel followed by radiotherapy plus capecitabine. At nine months, pancreatic tumor progression was observed at the level of the hepatic hilum with the appearance of a new pulmonary nodule suggestive of a second primary, confirmed by left lung biopsy. Systemic immunotherapy was then initiated with pembrolizumab, an immune checkpoint inhibitor targeting programmed cell death protein-1 that covers the two tumor types. The patient showed a complete metabolic response that was maintained throughout the treatment. The patient continues to be disease-free at 5.6 years since the start of immunotherapy. CONCLUSION These results suggest that the administration of pembrolizumab after chemoradiotherapy has a beneficial effect in patients with metastatic PDAC. To our knowledge, this is the first reported case of a patient with metastatic PDAC and metastatic lung cancer showing such a long-lasting complete response after pembrolizumab treatment without curative surgery. Further studies are required to determine biomarkers that identify PDAC patients most likely to benefit from this immunotherapy.

oncology,gastroenterology & hepatology
Advanced Cholangiocarcinoma With High Tumor Mutation Burden Achieving Complete Response to Immune Check Point Inhibitor

Hirohisa Okabe,Toshiro Masuda,Hidetoshi Nitta,Masahiro Tomita,Asuka Ono,Daisuke Kuroda,Hideyuki Kuroki,Masahiko Hirota,Taizo Hibi,Hideo Baba,Hiroki Sugita

DOI: https://doi.org/10.21873/anticanres.17135

Abstract:Background/aim: Genomic examination of tumor tissue has been clinically accepted, and the identification of actionable mutations for molecular-targeted therapy may provide substantial survival benefit for patients with advanced malignancies. Case report: A female patient in her 60s showed a stenosis of the afferent loop of the small intestine because of circumferential metastatic tumor 14 months after curative surgery for hilar cholangiocarcinoma. Chemotherapy with gemcitabine plus cisplatin was administered for 18 months. An oncopanel examination was performed during chemotherapy, and a high tumor mutation burden was revealed. At 38 months after surgery, a new recurrent tumor, 2.7 cm in size, was observed in the abdominal wall, which was histologically proven to be metastatic adenocarcinoma. Atezolizumab was administered. After three cycles of treatment, treatment was switched to pembrolizumab because of its acceptance by healthcare insurance. The recurrent tumors in the abdominal wall and small intestine disappeared 6 months after the administration of immune checkpoint inhibitor, and the patient has continued pembrolizumab, surviving for 76 months after surgery without any clinical evidence of tumor. Conclusion: Immune checkpoint blockade successfully prolonged the survival of a patient with advanced hilar cholangiocarcinoma with high tumor mutation burden, although the optimal number of mutations for such a successful response needs to be clarified.
Partial Response After Toripalimab Plus Anlotinib for Advanced Metaplastic Breast Carcinoma: A Case Report

Yang Fu,Jie Liu,Yu Jiang

DOI: https://doi.org/10.3389/fendo.2022.810747

IF: 6.055

2022-03-23

Frontiers in Endocrinology

Abstract:Metaplastic breast carcinoma (MBC) is an aggressive subtype of breast cancer, accounting for <1%. The clinical outcome is unknown due to the lack of treatment options. Here, we present the case of a 58-year-old woman with advanced MBC, in which standard adjuvant chemotherapy was unsuccessful. In the second-line therapy, she received anti-angiogenic(anlotinib) therapy plus chemotherapy. Finally, she was subsequently treated with immunotherapy (toripalimab) combined anlotinib and achieved partial response (PR); thus, immunotherapy plus anti-angiogenic therapy might be a novel option for advanced MBC patients.

endocrinology & metabolism
Immune-Therapy-Related Toxicity Events and Dramatic Remission after a Single Dose of Pembrolizumab Treatment in Metastatic Thymoma: A Case Report

Li Shen,Haiyan Chen,Qichun Wei

DOI: https://doi.org/10.3389/fimmu.2021.621858

IF: 7.3

2021-01-01

Frontiers in Immunology

Abstract:Immune checkpoint inhibitor therapy has become a promising option for the treatment of late-stage thymic epithelial tumors. In this manuscript, we presented a patient with metastatic thymoma administrated of anti-programmed cell death protein 1 (PD-1) antibody pembrolizumab. Although the patient underwent a rapid and dramatic response to one dose of pembrolizumab, she suffered a storm of immune-therapy related toxicity events (irAEs), including liver and kidney dysfunction, hypothyroidism and myocarditis. We didn’t observe >grade 3 irAEs, and proceed with pembrolizumab therapy after the function recovered. Although no guidelines recommend dose reduction of immunotherapy re-treating following initial irAEs, we optimize dose of pembrolizumab to minimize the irAEs induced by PD-1 antibody while maintaining clinical effectiveness. Excitingly, we observe remarkable tumor remission and mild toxicities of half dose of pembrolizumab in this case. In conclusion, the clinical utilization of immunotherapy is an encouraging therapeutic alternative for advanced thymomas. At the same time, patients have to be monitored very carefully, because of the risk to develop irAEs.
[Effectiveness of a mezlocillin-oxacillin combination in the treatment of gonorrhea].

U. Fischer-Brügge,D. Reinel

1983-10-07

Abstract:
Gross and fine neuromuscular performance at cold shivering

A. Meigal

DOI: https://doi.org/10.3402/ijch.v61i2.17449

2002-06-01

International Journal of Circumpolar Health

Abstract:Cold exposure may decrease the efficiency of voluntary motor activity due to a decrease of muscular temperature, and to involvement of the motor system in thermoregulator y motor behaviour and shivering thermogenesis.Traditionally, shivering thermogenesis is believed to comprise two patterns — 1) thermoregulatory muscle tone (or preshivering tone) and 2) cold shivering itself (Bur ton, Bronk, 1937). Since it was observed in animal experiments, this classification has been proved to be practical in human measurements. Shivering thermogenesis is aimed to prevent hypothermia by increasing heat production. Shivering and voluntary movements compete for common neural circuits (Kleinebeckel, Klussmann, 1990), and this may affect fine and gross performance. Mechanical tremor and elevated muscle tone during shivering may also influence accuracy of movements.This review focuses on the mechanisms of interaction between shivering thermogenesis and exercise and on the mechanisms which may compensate for this interaction.
Case report: Remarkable response to a novel combination of mitotane, etoposide, paraplatin, and sintilimab in a patient with metastatic adrenocortical carcinoma

Yan Weng,Lin Wang,Xiao-Yi Wang,Xin-Xiang Fan,Li Yan,Zhi-Hua Li,Shao-Ling Zhang

DOI: https://doi.org/10.3389/fendo.2023.1115893

IF: 6.055

2023-09-09

Frontiers in Endocrinology

Abstract:Background: Adrenocortical carcinoma (ACC) is a rare malignancy with a poor prognosis and limited treatment options for metastases. However, new effective regimens are emerging for specific conditions in metastatic ACC. Case presentation: We report a case of a 36-year-old man diagnosed with metastatic ACC who had a large left adrenal mass (158 mm × 112 mm) and multiple metastases in the liver and lungs. Genetic testing revealed a microsatellite instability-high (MSI-H) tumor, a splice mutation in MLH1, and a high tumor mutational burden (TMB). After the left adrenalectomy, he received sequential treatment with a combination of mitotane, etoposide, paraplatin (EP-M), and sintilimab. His condition has been assessed as a stable disease since the sixth cycle of the combined regimen. Conclusion: This case highlights the remarkable response of our patient's ACC with MSI-H tumor, MLH1 spice mutation, and high TMB to treatment with a novel combination of EP-M and sintilimab. Our findings suggest a promising therapeutic option for patients with similar molecular profiles.

endocrinology & metabolism
[A Case of Breast Carcinoma That Changed Subtype to Squamous Cell Carcinoma after Chemotherapy]

Kazuya Konishi,Jun Araya,Makoto Nagabuchi,Takashi Sakamoto,Jiro Ogino,Satoshi Hirano

Abstract:Metaplastic carcinoma is a rare histological malignancy, often triple-negative, and has a poor prognosis. Here, we report a case of breast cancer in which the primary lesion degenerated into squamous cell carcinoma(triple negative)after drug treatment for invasive ductal carcinoma(Luminal type). The patient was a 41-year-old woman who was diagnosed with Stage Ⅳ left breast cancer T2N2bM1(HEP)(ER 90%, PR 70%, HER2 2+, FISH-)at another hospital and participated in the PATHWAY study(tamoxifen plus goserelin plus palbociclib/placebo). Since the primary lesion and liver metastasis increased in size, the study was discontinued after 8 weeks. She was treated at our hospital thereafter, with capecitabine plus cyclophosphamide, palbociclib plus fulvestrant plus leuprorelin, paclitaxel plus bevacizumab, eribulin, EC therapy, and docetaxel. However, both the primary lesion and liver metastasis increased. In particular, the increase in primary lesion size was remarkable, and the QOL significantly reduced due to bleeding and exudation. Biopsy performed during docetaxel treatment revealed metaplastic/squamous cell carcinoma(ER-, PR-, HER2 0, Ki-67 90-100%)histopathological findings. BRCA and microsatellite instability tests were negative, and PDL1 expression was less than 1%. Although Mohs ointment was used, tumor bleeding, exudate, and stink were poorly controlled, and the patient experienced painful symptoms due to the weight of the tumor. Therefore, left mastectomy plus pectoralis major muscle resection was performed. The patient died one month after the operation.
Pembrolizumab Therapy Leading to Complete Remission for Recurrence of Pulmonary Metastases after their Resection and Radical Cystectomy following Gemcitabine and Cisplatin Therapy

Kyohei Ishida,Go Hasegawa,Takehisa Hashimoto,Yohei Ikeda,Noboru Hara,Tsutomu Nishiyama

DOI: https://doi.org/10.1155/2024/5586448

2024-01-17

Abstract:A 64-year-old man was diagnosed with invasive bladder and right lower ureteral urothelial cancer with right pelvic lymph node and lung metastases. He received four courses of gemcitabine and cisplatin therapy. He underwent lung metastasectomy and radical cystoprostatectomy, with not only primary lesions but also metastatic lesions showing a complete response. New multiple lung metastases were revealed five months after adjuvant chemotherapy. On starting pembrolizumab therapy, the metastatic lesions are notably reduced in size. He is currently receiving pembrolizumab therapy, and no recurrence has been observed for over one year.
Smart cookies. Access to information technology has been a contentious issue for nurses, but there is enthusiasm over its benefits for patients.

P. Dinsdale

DOI: https://doi.org/10.7748/ns.19.27.13.s30

2005-03-16

Nursing Standard

Abstract:

Skin response to pressure and ageing.

Metastatic Ovarian Tumor from Pancreatic Cancer Treated with Combined Immunotherapy: A Case Report

[A Case of Breast Metaplastic Carcinoma and Distant Metastasis with Complete Response to Immunotherapy]

Programmed Cell Death-1 Inhibitor Combination Treatment for Recurrent Proficient Mismatch Repair/ Miscrosatellite-Stable Type Endometrial Cancer: A Case Report.

Harnessing Listeria monocytogenes to target tumors

Case Report: Long-Term Response to Pembrolizumab Combined With Endocrine Therapy in Metastatic Breast Cancer Patients With Hormone Receptor Expression

Long Survival after Immunotherapy Plus Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma: A Case Report and Review of Literature

Case Report: Significant Response to Immune Checkpoint Inhibitor Camrelizumab in a Heavily Pretreated Advanced ER+/HER2− Breast Cancer Patient With High Tumor Mutational Burden

A Metastatic Intrahepatic Cholangiocarcinoma Treated with Programmed Cell Death 1 Inhibitor: a Case Report and Literature Review

Long-Lasting Complete Remission in a Patient With Metastatic Metaplastic Breast Cancer Treated With Immune Checkpoint Inhibitor and Chemotherapy: A Case Report and a Review of the Literature

A case report of a dramatic response to olaparib in a patient with metastatic pancreatic cancer harboring a germline BRCA2 mutation.

Metastatic pancreatic and lung cancer patient in complete remission following immunotherapy: A case report and review of literature

Advanced Cholangiocarcinoma With High Tumor Mutation Burden Achieving Complete Response to Immune Check Point Inhibitor

Partial Response After Toripalimab Plus Anlotinib for Advanced Metaplastic Breast Carcinoma: A Case Report

Immune-Therapy-Related Toxicity Events and Dramatic Remission after a Single Dose of Pembrolizumab Treatment in Metastatic Thymoma: A Case Report

[Effectiveness of a mezlocillin-oxacillin combination in the treatment of gonorrhea].

Gross and fine neuromuscular performance at cold shivering

Case report: Remarkable response to a novel combination of mitotane, etoposide, paraplatin, and sintilimab in a patient with metastatic adrenocortical carcinoma

[A Case of Breast Carcinoma That Changed Subtype to Squamous Cell Carcinoma after Chemotherapy]

Pembrolizumab Therapy Leading to Complete Remission for Recurrence of Pulmonary Metastases after their Resection and Radical Cystectomy following Gemcitabine and Cisplatin Therapy

Smart cookies. Access to information technology has been a contentious issue for nurses, but there is enthusiasm over its benefits for patients.